Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)

time to complete response (disappearance of all detectable clinical and radiographic evidenc of disease, and regression of lymph nodes) [ Time Frame: 6 weeks ]

Enrollment:

24

Study Start Date:

March 2003

Study Completion Date:

June 2004

Intervention Details:

Drug: Interferon Gamma-1b

100 or 200 mcg, SQ, 3x per week

Drug: Rituximab

375 mg per square meters, IV, 1x per week

Eligibility

Ages Eligible for Study:

18 Years to 80 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Relapsed or progressive low-grade/follicular NHL who are candidates for rituximab therapy

Patients who were on other therapy including CHOP or radiation

Previous therapy must have concluded 30 days prior to enrollment

Demonstrable CD20-positive tumor population in lymph nodes or bone marrow

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00057447